TM

Dr. Arzumanyan is an accomplished biotechnology researcher and executive with extensive experience in drug development and infectious disease research.  In her role as CDO, co-founder, and co-inventor at SFA Therapeutics, Dr. Arzumanyan has been instrumental in developing innovative therapeutic approaches.  Her groundbreaking work has led to the development of oral drugs for psoriasis (currently in Phase 1b clinical trial) and NASH/MASH/fibrosis, with FDA approval for Phase 1 clinical trial.

​

A significant aspect of her research involves the development of SYMBA (Synthetic Molecular Binding Agent) technology in collaboration with ThirdLaw Molecular, Inc.  Funded by the Defense Threat Reduction Agency (DTRA).  This innovative project creates an "artificial immune system" with applications in rapid diagnostics, biological agent sensors, and novel therapeutics.

​

Currently, Dr. Arzumanyan also serves as a Biotech Advisor for SmartGateVC, where she provides expert guidance to early-stage biotech companies and evaluates scientific and commercial potential of innovative projects, particularly those involving AI in healthcare.​​​